By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Symphogen A/S 

Building 37
Lyngby    DK-2800  Denmark
Phone: 45-45-26-50-50 Fax: 45-45-26-50-60



Company News
Symphogen Names New Chief Financial Officer 9/14/2016 11:08:27 AM
Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director 8/18/2016 6:20:58 AM
Symphogen Advances Sym015 Into Clinical Development Using Selexis SA SGEs (Selexis Genetic Elements) 6/29/2016 9:00:11 AM
Symphogen Announces The Appointment Of Jeffrey H. Buchalter And Christoffer Søderberg As Non-Executive Directors 5/11/2016 10:49:25 AM
Symphogen Initiates Anti-MET Clinical Program And Presents Pre-Clinical Anti-MET Data At Annual AACR Meeting April 18th In New Orleans 4/12/2016 9:34:13 AM
Baxalta (BXLT) to Fork Over Up to $1.6 Billion for Symphogen Products 1/4/2016 5:47:09 AM
Symphogen A/S Announces Closing Of A EUR 67.5 Million Financing Subscribed By Existing Investors 10/22/2015 10:53:43 AM
Symphogen A/S’s Antibody Mixtures Highlighted In Three Peer-Reviewed Journals 5/28/2015 9:55:57 AM
Merck KGaA (MKGAF.PK) Walks Away From $625 Million Deal With Symphogen A/S 1/29/2015 7:17:43 AM
Symphogen A/S Licenses The Selexis SA SUREtechnology Expression Platform And Cell Line 12/9/2014 11:29:21 AM